Nancy Kienka, NP
Family · Oklahoma City, OKNPI 1316353568
Payments from drug & device makers
Across 602 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- GSK$1K
- Novo Nordisk$1K
- Lilly USA, LLC$987
- Pfizer$762
- plus $3K from 24 others
What the payments were for
- Food & beverage$9,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $1,785 |
| AstraZeneca | 60 | $1,196 |
| GSK | 89 | $1,180 |
| Novo Nordisk | 73 | $1,064 |
| Lilly USA, LLC | 67 | $987 |
| Pfizer | 49 | $762 |
| Amgen(2 entities) | 24 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $386 |
| Exact Sciences | 18 | $284 |
| Boehringer Ingelheim | 14 | $253 |
| Bayer | 14 | $242 |
| Merck | 15 | $227 |
| Antares Pharma, Inc. | 9 | $181 |
| Biohaven Pharmaceuticals, Inc. | 7 | $112 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $82 |
| Nabriva Therapeutics, PLC | 3 | $73 |
| Eisai Inc. | 4 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Abbott | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Almatica Pharma LLC | 1 | $14 |
| Seqirus USA Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,619 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $52,250 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $35,902 |
| OzempicSemaglutide | 24 | $29,138 |
| FarxigaDapagliflozin Propanediol | 13 | $20,067 |
| MounjaroTirzepatide | 15 | $17,423 |
| JanuviaSitagliptin Phosphate | 11 | $16,465 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $8,442 |
| Levothyroxine Sodium | 100 | $1,452 |
| Gabapentin | 94 | $1,340 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,285 |
| Rosuvastatin Calcium | 33 | $1,150 |
| Omeprazole | 59 | $1,068 |
| Celecoxib | 20 | $953 |
| Atorvastatin Calcium | 71 | $703 |
| Montelukast Sodium | 52 | $697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $987 | $69,67353 claims |
| GSKTrelegy Ellipta | $1,180 | $35,90227 claims |
| Novo NordiskOzempic | $1,064 | $29,13824 claims |
| MerckJanuvia, Janumet Xr | $227 | $24,90622 claims |
| AstraZenecaFarxiga | $1,196 | $20,06713 claims |
| AbbVieSynthroid | $1,785 | $39112 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $28135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.